DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" report to their offering.
The NSCLC market in Asia-Pacific is forecast to grow substantially, from $3 billion in 2016 to $6.2 billion in 2023, at a compound annual growth rate (CAGR) of 10.8%.
The percentage of people above 65 in 2016 and 2014 was 27.2% and 25.8% in Japan; 10.3% and 9.6% in China; 6% and 5.8% in India; 15.8% and 15% in Australia; and 13.5% and 13% in South Korea. The increase in the ageing population will drive NSCLC prevalence. Smoking is the main cause of lung cancer, ahead of radon gas, inhalation of chemical carcinogens and genetic factors. Although the number of smokers is falling in Asia-Pacific (APAC), the prevalence of NSCLC is increasing.
New targeted and immuno-therapies will drive market growth due to premium pricing and strong clinical performances, but they will also increase the degree of NSCLC market segmentation and the complexity of the treatment algorithm, owing to their enhanced efficacy in specific patient populations. The limited effect of patent expiry on the NSCLC market is one of the main reasons for the substantial growth in value expected in the forecast period, as the introduction of numerous therapies will not be offset by generic erosion; instead, premium therapies will occupy a larger market share for much of the forecast period in APAC.
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly
- Merck & Co
Key Topics Covered:
2 Marketed Products
3 Pipeline Analysis
4 Clinical Trial Analysis
5 Multi-scenario Forecast
6 Drivers and Barriers
7 Deals and Strategic Consolidations
For more information about this report visit http://www.researchandmarkets.com/research/3f32xh/nonsmall_cell